Moberg Pharma AB Sustainability Reports
Moberg Pharma AB is a Swedish pharmaceutical company focused on the development and commercialization of proprietary innovative topical treatments for skin diseases and nail conditions. Its lead product, MOB-015 (Terclara), is a topical treatment for onychomycosis (nail fungus).
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300XFXK7DVGDRP410
FIGI: BBG001TFZHR7
13 reports from 2008 to 2025
